123 related articles for article (PubMed ID: 21406600)
21. Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren.
Tapaninen T; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2010 Sep; 66(9):865-70. PubMed ID: 20496145
[TBL] [Abstract][Full Text] [Related]
22. Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys.
Tsukimoto M; Ohashi R; Torimoto N; Togo Y; Suzuki T; Maeda T; Kagawa Y
Biopharm Drug Dispos; 2015 Jan; 36(1):15-33. PubMed ID: 25264342
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension.
Sullivan JE; Keefe D; Zhou Y; Satlin L; Fang H; Yan JH
Clin Pediatr (Phila); 2013 Jul; 52(7):599-607. PubMed ID: 23610239
[TBL] [Abstract][Full Text] [Related]
24. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
25. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
26. Impact of P-gp inhibition on systemic exposure of pralsetinib and dosing considerations.
Suchomel J; Agarwal P; Anders D; Hughes K; Tang Y; Sane R; Scalori A; Sharma S; Cheeti S
Clin Transl Sci; 2024 Jun; 17(6):e13818. PubMed ID: 38807449
[TBL] [Abstract][Full Text] [Related]
27. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
28. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
[TBL] [Abstract][Full Text] [Related]
29. Drug interactions with simvastatin.
Med Lett Drugs Ther; 2008 Oct; 50(1297):83-4. PubMed ID: 18927522
[No Abstract] [Full Text] [Related]
30. Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters.
Katsube T; Inoue Y; Fukuhara T; Kano T; Wajima T
Eur J Clin Pharmacol; 2020 Dec; 76(12):1659-1665. PubMed ID: 32666123
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
Yan JH; Jarugula V; Sabo R; Papst CC; Zhang J; Dole WP
J Clin Pharmacol; 2012 May; 52(5):645-55. PubMed ID: 21659626
[TBL] [Abstract][Full Text] [Related]
32. Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study.
Maeda K; Takano J; Ikeda Y; Fujita T; Oyama Y; Nozawa K; Kumagai Y; Sugiyama Y
Clin Pharmacol Ther; 2011 Aug; 90(2):263-70. PubMed ID: 21716273
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
Ieiri I; Tsunemitsu S; Maeda K; Ando Y; Izumi N; Kimura M; Yamane N; Okuzono T; Morishita M; Kotani N; Kanda E; Deguchi M; Matsuguma K; Matsuki S; Hirota T; Irie S; Kusuhara H; Sugiyama Y
J Clin Pharmacol; 2013 Jun; 53(6):654-61. PubMed ID: 23381882
[TBL] [Abstract][Full Text] [Related]
34. Influence of ABCB1 gene polymorphisms and P-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers.
Ansermot N; Rebsamen M; Chabert J; Fathi M; Gex-Fabry M; Daali Y; Besson M; Rossier M; Rudaz S; Hochstrasser D; Dayer P; Desmeules J
Drug Metab Lett; 2008 Apr; 2(2):76-82. PubMed ID: 19356075
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
[TBL] [Abstract][Full Text] [Related]
36. [Pharmacogenetic analysis of the absorption kinetics of cyclosporine in a population of Spanish cardiac transplant patients].
Isla Tejera B; Aumente Rubio MD; Martínez-Moreno J; Reyes Malia M; Arizón JM; Suárez García A
Farm Hosp; 2009; 33(6):324-9. PubMed ID: 20038391
[TBL] [Abstract][Full Text] [Related]
37. Re: Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Rao N
J Clin Pharmacol; 2011 May; 51(5):784. PubMed ID: 20671297
[No Abstract] [Full Text] [Related]
38. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.
Garg V; van Heeswijk R; Lee JE; Alves K; Nadkarni P; Luo X
Hepatology; 2011 Jul; 54(1):20-7. PubMed ID: 21618566
[TBL] [Abstract][Full Text] [Related]
39. Itraconazole and domperidone: a placebo-controlled drug interaction study.
Yoshizato T; Kotegawa T; Imai H; Tsutsumi K; Imanaga J; Ohyama T; Ohashi K
Eur J Clin Pharmacol; 2012 Sep; 68(9):1287-94. PubMed ID: 22418831
[TBL] [Abstract][Full Text] [Related]
40. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
Padhi D; Salfi M; Emery M
Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
